Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

1.169 +0.059 (+5.34%)
Streaming Delayed Price Updated: 10:43 AM EDT, Apr 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers SAI.TECH Global Corporation (NASDAQ: SAI) jumped 269% to $5.61 after gaining around 25% on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Navidea Biopharmaceuticals Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 318% to $29.80 in pre-market trading after gaining more than 345% on Thursday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time for another dive into the biggest pre-market stock movers with all the latest news traders need to know about for Friday! 
Via InvestorPlace
Nasdaq Rises 2%; Consolidated Communications Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Thursday. The Dow traded up 1.09% to 34,013.93 while the NASDAQ rose 2% to 12,167. The S&P 500,... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Dow Rises Over 100 Points; Delta Air Lines Earnings Miss Views
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Thursday. The Dow traded up 0.43% to 33,790.58 while the NASDAQ rose 1.36% to 12,091.38. The S&P... 
Via Benzinga
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday. 
Via Benzinga
Why Is SAB Therapeutics Stock Trading Higher Today?
SAB Therapeutics (NASDAQ: SABS) shares are trading higher on Thursday after the company said it has been granted Fast Track designation from the FDA for SAB-176 influenza immunotherapy with high... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those... 
Via Benzinga
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Provides Company Update for Full Year 2022
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 81 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 89 stocks made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 469 companies hit new 52-week lows. 
Via Benzinga
SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
Conference to take place Feb. 6-9 in New York 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Receives Additional $8.2M In Closeout Of COVID-19 DoD Contract
SAB Biotherapeutics (NASDAQ: SABS) has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
Study shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is well tolerated; next step is investigational new drug (IND) filing 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics' Type 1 Diabetes Candidate Moves One Step Closer To Enter Human Trials With Completion Of Toxicology Study
SAB Biotherapeutics (NASDAQ: SABS) has completed an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic to prevent and/or delay onset and progression of type 1 diabetes (T1D)... 
Via Benzinga
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 116 companies set new 52-week lows. 
Via Benzinga
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022
Via Benzinga
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
Study of SAB’s fully-human polyclonal therapeutic to delay onset or progression of type 1 diabetes is the last step before investigational new drug (IND) filing 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.